Literature DB >> 9653597

Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration.

C A Abbott1, L Vileikyte, S Williamson, A L Carrington, A J Boulton.   

Abstract

OBJECTIVE: To investigate longitudinally prognostic factors for foot ulceration in a large population of diabetic patients with established neuropathy. RESEARCH DESIGN AND METHODS: A double-blind multicenter study of a potential new agent for diabetic neuropathy provided the opportunity for this 1-year investigation since intervention demonstrated no efficacy in the condition. A total of 1,035 patients with NIDDM and IDDM were included. Inclusion criteria were vibration perception threshold (VPT) at the great toe > or = 25 V in at least one foot and < or = 50 V in both feet, normal peripheral circulation, and no previous foot ulceration. VPT and clinical components of the Michigan diabetic polyneuropathy (DPN) score were assessed at baseline and subsequent visits.
RESULTS: After 1 year, the incidence of first foot ulcers for the total population was 7.2%. Neuropathy parameters were the same between the treatment and placebo groups at baseline and were unchanged at 1 year; therefore, baseline data were combined for multiple regression analysis. VPT, age, and Michigan DPN scores for muscle strength and reflexes were significant independent predictors for first foot ulceration (P < 0.01). For each 1-U increase in VPT values at baseline, the hazard of the first foot ulcer increased by 5.6%. Similarly, for each 1-U increase in muscle strength and reflex components of the Michigan DPN scores, the hazard of the first foot ulcer increased by 5.0%.
CONCLUSIONS: Tests of VPT and Michigan DPN scores for muscle strength and reflexes are useful clinical predictors for foot ulceration in diabetic patients with established neuropathy. The rate of subsequent ulceration in the following year was alarmingly high, however, despite standardized foot care education at baseline and regular follow-up visits.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653597     DOI: 10.2337/diacare.21.7.1071

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  64 in total

Review 1.  Risk factors for diabetic neuropathy and foot ulceration.

Authors:  A Adler
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

2.  Management of painful diabetic neuropathy: what is new or in the pipeline for 2007?

Authors:  Dan Ziegler
Journal:  Curr Diab Rep       Date:  2007-12       Impact factor: 4.810

Review 3.  Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot.

Authors:  Mitra Tavakoli; Ioannis N Petropoulos; Rayaz A Malik
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

Review 4.  Measurement of somatic neuropathy for clinical practice and clinical trials.

Authors:  L V Scott; S Tesfaye
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 5.  In vivo confocal microscopy of the ocular surface: from bench to bedside.

Authors:  Edoardo Villani; Christophe Baudouin; Nathan Efron; Pedram Hamrah; Takashi Kojima; Sanjay V Patel; Stephen C Pflugfelder; Andrey Zhivov; Murat Dogru
Journal:  Curr Eye Res       Date:  2013-11-11       Impact factor: 2.424

6.  Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure.

Authors:  José I Fernández-Montequín; Blas Y Betancourt; Gisselle Leyva-Gonzalez; Ernesto L Mola; Katia Galán-Naranjo; Mayte Ramírez-Navas; Sergio Bermúdez-Rojas; Felix Rosales; Elizeth García-Iglesias; Jorge Berlanga-Acosta; Ricardo Silva-Rodriguez; Marianela Garcia-Siverio; Luis H Martinez
Journal:  Int Wound J       Date:  2009-02       Impact factor: 3.315

7.  Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study.

Authors:  José I Fernández-Montequín; Carmen M Valenzuela-Silva; Odalys González Díaz; William Savigne; Natasha Sancho-Soutelo; Fidel Rivero-Fernández; Pablo Sánchez-Penton; Lourdes Morejón-Vega; Heriberto Artaza-Sanz; Arístides García-Herrera; Cecilio González-Benavides; Carlos M Hernández-Cañete; Alberto Vázquez-Proenza; Jorge Berlanga-Acosta; Pedro A López-Saura
Journal:  Int Wound J       Date:  2009-12       Impact factor: 3.315

8.  Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.

Authors:  José I Fernández-Montequín; Ena Infante-Cristiá; Carmen Valenzuela-Silva; Neobalis Franco-Pérez; William Savigne-Gutierrez; Heriberto Artaza-Sanz; Lourdes Morejón-Vega; Cecilio González-Benavides; Osvaldo Eliseo-Musenden; Elizeth García-Iglesias; Jorge Berlanga-Acosta; Ricardo Silva-Rodríguez; Blas Y Betancourt; Pedro A López-Saura
Journal:  Int Wound J       Date:  2007-10-22       Impact factor: 3.315

9.  Cognitive function is not associated with recurrent foot ulcers in patients with diabetes and neuropathy.

Authors:  Christof Kloos; Franziska Hagen; Claudia Lindloh; Anke Braun; Karena Leppert; Nicolle Müller; Gunter Wolf; Ulrich A Müller
Journal:  Diabetes Care       Date:  2009-02-24       Impact factor: 17.152

10.  Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Authors:  Dan Ziegler; Lusine Movsesyan; Boris Mankovsky; Irina Gurieva; Zhangentkhan Abylaiuly; Igor Strokov
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.